Science | Innate Pharma

ANKET: Our NK cell engager platform

Thu, 06/10/2021 - 07:00

Click here to learn more about ANKET^TM

Read more about ANKET: Our NK cell engager platform

Interview of Eric Vivier “The new generation of NK cell therapies”

Fri, 02/05/2021 - 08:00

Interview Eric Vivier "The new generation of NK cell therapies"

Read more about Interview of Eric Vivier “The new generation of NK cell therapies”

How NK cells work

Fri, 01/01/2021 - 12:00

Read more about How NK cells work

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Thu, 05/30/2019 - 07:00

Read more about Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

CellPress : Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity | Eric Vivier

Thu, 05/30/2019 - 10:30

Read more about CellPress : Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity | Eric Vivier

Conference call replay (October 22th, 2018) ESMO 2018: Phase II trial of monalizumab and cetuximab

Mon, 10/22/2018 - 18:30

Download the presentation

Read more about Conference call replay (October 22th, 2018) ESMO 2018: Phase II trial of monalizumab and cetuximab

Innate Pharma - Converting science into the clinic

Wed, 03/28/2018 - 11:45

Interview of Mondher Mahjoubi, CEO, and Eric Vivier, CSO, in Biotech Strategy Blog.

Access to the article

(full article restricted to subscribers)

Read more about Innate Pharma - Converting science into the clinic

Subscribe to Science